Switch theme
Sign up to access all valuation multiples
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.
1967
14.8K+
LTM Revenue $4.6B
LTM EBITDA $1.1B
$15.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biomerieux has a last 12-month revenue (LTM) of $4.6B and a last 12-month EBITDA of $1.1B.
In the most recent fiscal year, Biomerieux achieved revenue of $4.5B and an EBITDA of $1.0B.
Biomerieux expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biomerieux valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.6B | XXX | $4.5B | XXX | XXX | XXX |
| Gross Profit | $2.6B | XXX | $2.5B | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $1.1B | XXX | $1.0B | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $732M | XXX | $717M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $527M | XXX | $485M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biomerieux's stock price is EUR 117 (or $131).
Biomerieux has current market cap of EUR 13.8B (or $15.5B), and EV of EUR 13.8B (or $15.5B).
See Biomerieux trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.5B | $15.5B | XXX | XXX | XXX | XXX | $4.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biomerieux has market cap of $15.5B and EV of $15.5B.
Biomerieux's trades at 3.5x EV/Revenue multiple, and 15.4x EV/EBITDA.
Equity research analysts estimate Biomerieux's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biomerieux has a P/E ratio of 29.4x.
See valuation multiples for Biomerieux and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.5B | XXX | $15.5B | XXX | XXX | XXX |
| EV (current) | $15.5B | XXX | $15.5B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 14.3x | XXX | 15.4x | XXX | XXX | XXX |
| EV/EBIT | 21.2x | XXX | 21.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.4x | XXX | 31.9x | XXX | XXX | XXX |
| EV/FCF | 31.3x | XXX | 43.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiomerieux's last 12 month revenue growth is 7%
Biomerieux's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Biomerieux's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biomerieux's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biomerieux and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomerieux acquired XXX companies to date.
Last acquisition by Biomerieux was XXXXXXXX, XXXXX XXXXX XXXXXX . Biomerieux acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biomerieux founded? | Biomerieux was founded in 1967. |
| Where is Biomerieux headquartered? | Biomerieux is headquartered in France. |
| How many employees does Biomerieux have? | As of today, Biomerieux has 14.8K+ employees. |
| Who is the CEO of Biomerieux? | Biomerieux's CEO is Mr. Alexandre Merieux. |
| Is Biomerieux publicy listed? | Yes, Biomerieux is a public company listed on PAR. |
| What is the stock symbol of Biomerieux? | Biomerieux trades under BIM ticker. |
| When did Biomerieux go public? | Biomerieux went public in 2004. |
| Who are competitors of Biomerieux? | Similar companies to Biomerieux include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Biomerieux? | Biomerieux's current market cap is $15.5B |
| What is the current revenue of Biomerieux? | Biomerieux's last 12 months revenue is $4.6B. |
| What is the current revenue growth of Biomerieux? | Biomerieux revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Biomerieux? | Current revenue multiple of Biomerieux is 3.4x. |
| Is Biomerieux profitable? | Yes, Biomerieux is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biomerieux? | Biomerieux's last 12 months EBITDA is $1.1B. |
| What is Biomerieux's EBITDA margin? | Biomerieux's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Biomerieux? | Current EBITDA multiple of Biomerieux is 14.3x. |
| What is the current FCF of Biomerieux? | Biomerieux's last 12 months FCF is $496M. |
| What is Biomerieux's FCF margin? | Biomerieux's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Biomerieux? | Current FCF multiple of Biomerieux is 31.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
